J Invest Dermatol 2013 Jan 16;133(1):274-6. Epub 2012 Aug 16.
Seccio Dermatologia, Departament de Medicina, Hospital Universitari Vall d’Hebron, Universitat Autonomade Barcelona, Spain.
Clin Cancer Res 2020 Dec 22. Epub 2020 Dec 22.
Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
Purpose: Targeting RAF for antitumor therapy in RAS-mutant tumors holds promise. Herein, we describe in detail novel properties of the type II RAF inhibitor, LXH254.Experimental Design: LXH254 was profiled in biochemical, , and assays, including examining the activities of the drug in a large panel of cancer-derived cell lines and a comprehensive set of models. Read More
Mol Cancer Ther 2021 02 3;20(2):238-249. Epub 2020 Dec 3.
Bioscience, Oncology R&D, AstraZeneca, Cambridge, England, United Kingdom.
The RAS-regulated RAF-MEK1/2-ERK1/2 (RAS/MAPK) signaling pathway is a major driver in oncogenesis and is frequently dysregulated in human cancers, primarily by mutations in or genes. The clinical benefit of inhibitors of this pathway as single agents has only been realized in -mutant melanoma, with limited effect of single-agent pathway inhibitors in -mutant tumors. Combined inhibition of multiple nodes within this pathway, such as MEK1/2 and ERK1/2, may be necessary to effectively suppress pathway signaling in -mutant tumors and achieve meaningful clinical benefit. Read More
Ann Surg Oncol 2020 Sep 6;27(9):3478-3485. Epub 2020 Apr 6.
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Haidian District, Beijing, China.
Background: The clinicopathological and survival profiles across primary sites in acral melanoma (AM) are still controversial and unclear.Methods: This is a multi-center retrospective study. Clinicopathological data of AM patients diagnosed between 1 January 2000 and 31 December 2017 from 6 large tertiary hospitals in China were extracted. Read More
Clin Rheumatol 2020 Jun 18;39(6):1851-1858. Epub 2020 Jan 18.
Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland.
Aims: To (1) determine the reliability and validity of the Bristol Rheumatoid Arthritis Fatigue scale (BRAF-NRS) in patients with psoriatic arthritis (PsA) and (2) examine possible clinical associations of worse fatigue in PsA.Methods: Study phase 1: BRAF-NRS scale validation cohort. A consecutive cohort of 70 PsA patients was recruited to complete the 3-item BRAF-NRS and the 13-item Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) questionnaires, alongside disease activity assessment. Read More
Nat Commun 2019 11 14;10(1):5157. Epub 2019 Nov 14.
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, 02115, MA, USA.
Most targeted cancer therapies fail to achieve complete tumor regressions or attain durable remissions. To understand why these treatments fail to induce robust cytotoxic responses despite appropriately targeting oncogenic drivers, here we systematically interrogated the dependence of cancer cells on the BCL-2 family of apoptotic proteins after drug treatment. We observe that multiple targeted therapies, including BRAF or EGFR inhibitors, rapidly deplete the pro-apoptotic factor NOXA, thus creating a dependence on the anti-apoptotic protein MCL-1. Read More